vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and NexPoint Real Estate Finance, Inc. (NREF). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $11.1M, roughly 1.7× NexPoint Real Estate Finance, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -90.7%, a 307.3% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -48.8%).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.
NAMS vs NREF — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $11.1M |
| Net Profit | $-17.4M | $24.0M |
| Gross Margin | — | — |
| Operating Margin | -186.1% | — |
| Net Margin | -90.7% | 216.6% |
| Revenue YoY | 740.1% | -48.8% |
| Net Profit YoY | 55.5% | 58.7% |
| EPS (diluted) | $-0.15 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $11.1M | ||
| Q3 25 | — | $12.5M | ||
| Q2 25 | $19.1M | $12.1M | ||
| Q1 25 | — | $11.5M | ||
| Q4 24 | $12.8M | $21.7M | ||
| Q3 24 | $29.1M | $12.5M | ||
| Q2 24 | — | $6.7M | ||
| Q1 24 | — | $-12.8M |
| Q4 25 | — | $24.0M | ||
| Q3 25 | — | $50.9M | ||
| Q2 25 | $-17.4M | $22.3M | ||
| Q1 25 | — | $26.0M | ||
| Q4 24 | $-92.2M | $15.2M | ||
| Q3 24 | $-16.6M | $23.3M | ||
| Q2 24 | — | $12.1M | ||
| Q1 24 | — | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -186.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -338.5% | — | ||
| Q3 24 | -85.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 216.6% | ||
| Q3 25 | — | 407.0% | ||
| Q2 25 | -90.7% | 184.5% | ||
| Q1 25 | — | 225.6% | ||
| Q4 24 | -721.7% | 69.9% | ||
| Q3 24 | -57.2% | 186.4% | ||
| Q2 24 | — | 179.7% | ||
| Q1 24 | — | 114.3% |
| Q4 25 | — | $0.47 | ||
| Q3 25 | — | $1.14 | ||
| Q2 25 | $-0.15 | $0.54 | ||
| Q1 25 | — | $0.70 | ||
| Q4 24 | $-0.91 | $0.71 | ||
| Q3 24 | $-0.18 | $0.74 | ||
| Q2 24 | — | $0.40 | ||
| Q1 24 | — | $-0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $31.1M |
| Total DebtLower is stronger | — | $771.2M |
| Stockholders' EquityBook value | $778.5M | $388.0M |
| Total Assets | $815.1M | $5.3B |
| Debt / EquityLower = less leverage | — | 1.99× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $31.1M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | $739.2M | $9.1M | ||
| Q1 25 | — | $19.2M | ||
| Q4 24 | $834.2M | $3.9M | ||
| Q3 24 | $422.7M | $34.7M | ||
| Q2 24 | — | $4.3M | ||
| Q1 24 | — | $13.5M |
| Q4 25 | — | $771.2M | ||
| Q3 25 | — | $720.9M | ||
| Q2 25 | — | $815.6M | ||
| Q1 25 | — | $831.5M | ||
| Q4 24 | — | $799.3M | ||
| Q3 24 | — | $815.5M | ||
| Q2 24 | — | $861.0M | ||
| Q1 24 | — | $843.3M |
| Q4 25 | — | $388.0M | ||
| Q3 25 | — | $375.4M | ||
| Q2 25 | $778.5M | $348.2M | ||
| Q1 25 | — | $343.7M | ||
| Q4 24 | $757.5M | $336.5M | ||
| Q3 24 | $378.9M | $335.8M | ||
| Q2 24 | — | $327.5M | ||
| Q1 24 | — | $327.1M |
| Q4 25 | — | $5.3B | ||
| Q3 25 | — | $5.3B | ||
| Q2 25 | $815.1M | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | $864.6M | $5.4B | ||
| Q3 24 | $439.2M | $5.7B | ||
| Q2 24 | — | $6.6B | ||
| Q1 24 | — | $7.1B |
| Q4 25 | — | 1.99× | ||
| Q3 25 | — | 1.92× | ||
| Q2 25 | — | 2.34× | ||
| Q1 25 | — | 2.42× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | 2.43× | ||
| Q2 24 | — | 2.63× | ||
| Q1 24 | — | 2.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $-4.5M |
| Free Cash FlowOCF − Capex | $-37.8M | — |
| FCF MarginFCF / Revenue | -197.2% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-4.5M | ||
| Q3 25 | — | $8.1M | ||
| Q2 25 | $-37.7M | $3.3M | ||
| Q1 25 | — | $16.0M | ||
| Q4 24 | $-37.5M | $4.4M | ||
| Q3 24 | $-12.5M | $14.7M | ||
| Q2 24 | — | $-7.5M | ||
| Q1 24 | — | $17.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-37.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -197.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -293.5% | — | ||
| Q3 24 | -43.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.62× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 0.63× | ||
| Q2 24 | — | -0.62× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
